DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: progesterone

Summary for Generic Name: progesterone

Tradenames:5
Patents:4
Applicants:12
NDAs:12
Drug Master File Entries: see list44
Suppliers: see list8
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details

Pharmacology for Ingredient: progesterone

Ingredient-typeProgesterone
Drug ClassProgesterone

Clinical Trials for: progesterone

Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone
Status: Recruiting Condition: Progesterone Supplementation

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor
Status: Recruiting Condition: Preterm Labor

Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)
Status: Completed Condition: Infertility

Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen
Status: Not yet recruiting Condition: Endometrial Hyperplasia; Endometrial Cancer

Comparing IM vs. Vaginal Progesterone for Pre-term Birth
Status: Completed Condition: Infant, Premature; Premature Birth

Sexual Absorption of Vaginal Progesterone
Status: Completed Condition: Infertility; Pregnancy

A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)
Status: Completed Condition: Infertility

Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration
Status: Completed Condition: Postmenopausal Endometrium

Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)
Status: Completed Condition: Infertility

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
Status: Recruiting Condition: Focus of the Study is to Determine if Oral Progesterone Administration Attenuates Drug-induced QT Interval Lengthening in Women

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057Jun 21, 2007RXYes7,393,543<disabled>YENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057Jun 21, 2007RXYes7,320,800<disabled>SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057Jun 21, 2007RXYes7,300,664<disabled>SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
Alza
PROGESTASERT
progesterone
INSERT, EXTENDED RELEASE;INTRAUTERINE017553Approved Prior to Jan 1, 1982DISCNNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc